Market Currents
Clovis Oncology (CLVS) shares collapse 42% after its CO-101 treatment failed to prolong the...
-
Monday, November 12, 2012, 8:39 AM ETClovis Oncology (CLVS) shares collapse 42% after its CO-101 treatment failed to prolong the survival of patients with pancreatic cancer vs gemcitabine in a phase III study. Clovis is now ending the development of the drug pending further evaluation of the trial data.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
